B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.

Related Articles

B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.

Clin Adv Hematol Oncol. 2016 Jan;14(1):55-65

Authors: Koehrer S, Burger JA

Abstract
B-cell receptor (BCR) signaling has emerged as a key pathway for the expansion of neoplastic B-cell clones in several B-cell malignancies. The mechanisms that activate BCR signaling differ substantially among subtypes of B-cell lymphoma and leukemia. These include BCR stimulation by foreign or self-antigens, or the acquisition of mutations in components of the BCR pathway that result in autonomous or enhanced antigen-induced BCR signaling. Targeting BCR signaling with selective inhibitors of the BCR-associated kinases Bruton's tyrosine kinase, spleen tyrosine kinase, and phosphoinositide 3-kinase delta induces high response rates in patients with chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, and diffuse large B-cell lymphoma of the activated B-cell-like subtype and is currently transforming the therapeutic landscape in these diseases. Here we review the mechanisms of BCR activation that govern growth and survival of malignant B cells. We also summarize recent clinical trials of BCR inhibitors, with a focus on the most clinically advanced agents.

PMID: 27057669 [PubMed - indexed for MEDLINE]

http://ift.tt/2icWmnP